# GlaxoSmithKline FDA advisory committee votes in favour of Belantamab mafodotin

- Link: https://www.directorstalkinterviews.com/glaxosmithkline-fda-advisory-committee-votes-in-favour-of-belantamab-mafodotin/412842816
- Published: 2020-07-15T07:36:42+01:00
- Author: Amilia Stone

**[GlaxoSmithKline](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)
plc **([LON:GSK](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l))
has announced the US Food and Drug Administration Oncologic Drugs Advisory Committee
voted 12-0 in favour of the demonstrated benefit of monotherapy treatment with belantamab
mafodotin outweighing the risks for patients with relapsed or refractory multiple
myeloma who have received at least four prior therapies including an immunomodulatory
agent, a proteasome inhibitor and an anti-CD38 antibody. Two committee members could
not participate in the final vote.

The recommendation was based on data from the DREAMM (DRiving Excellence in Approaches
to Multiple Myeloma) clinical trial programme, including the pivotal DREAMM-2 study
which enrolled heavily pre-treated patients who had actively progressing multiple
myeloma that had worsened despite current standard of care.^([i]) The six-month 
primary results from the study were published in _The Lancet Oncology_ in December
2019 and serve as the basis for the Biologics License Application (BLA).

The FDA will consider the recommendation of the committee but is not obligated to
follow it. The FDA granted breakthrough therapy designation to belantamab mafodotin
in 2017 and priority review designation for the BLA earlier this year. A Marketing
Authorisation Application for belantamab mafodotin also is under accelerated assessment
by the European Medicines Agency.

Belantamab mafodotin is not currently approved for use anywhere in the world.

> **Dr Axel Hoos, Senior Vice President and Head of Oncology R&D, GlaxoSmithKline
> said: **“We are pleased the committee recognised the potential for belantamab 
> mafodotin to help patients who have relapsed or refractory multiple myeloma, an
> incurable disease with limited treatment options. We look forward to working with
> the FDA as they complete their review of our Biologics License Application.”

Share on:
